Christopher M. Nutting
The Royal Marsden NHS Foundation Trust
Quality of lifeCancerInternal medicineRadiologySurgeryPathologyOncologyMedical physicsHead and neck cancerChemotherapyChemoradiotherapyDysphagiaTargeted therapyNuclear medicineIn patientHead and neckIntensity modulated radiotherapyRadiation therapyMedicine
Publications 440
#1Amit Gupta (The Royal Marsden NHS Foundation Trust)
#2Alex Dunlop (ICR: Institute of Cancer Research)H-Index: 12
Last. KH Wong (The Royal Marsden NHS Foundation Trust)H-Index: 4
view all 12 authors...
Introduction The Elekta Unity MR-Linac (MRL) has enabled adaptive radiotherapy (ART) for patients with head and neck cancers (HNC). Adapt-To-Shape-Lite (ATS-Lite) is a novel Adapt-to-Shape strategy that provides ART without requiring daily clinician presence to perform online target and organ at risk (OAR) delineation. In this study we compared the performance of our clinically-delivered ATS-Lite strategy against three Adapt-To-Position (ATP) variants: Adapt Segments (ATP-AS), Optimise Weights (...
#1Justine Tyler (The Royal Marsden NHS Foundation Trust)H-Index: 3
#2David Bernstein (ICR: Institute of Cancer Research)H-Index: 3
Last. Christopher M. Nutting (ICR: Institute of Cancer Research)H-Index: 73
view all 9 authors...
Abstract null null This study aimed to assess the impact of the margin applied to the clinical target volume, to create the planning target volume, on plan quality of a novel dysphagia-optimised intensity modulated radiotherapy technique developed within a head and neck cancer multicentre randomised controlled trial. Protocol compliant plans were used for a single benchmark planning case. null Larger margins were associated with higher doses to adjacent organs at risk, particularly the inferior ...
#2KH WongH-Index: 4
Last. Kevin J. HarringtonH-Index: 101
view all 6 authors...
#9GD Patel (UCL: University College London)H-Index: 1
#1M. Vreugdenhil (Queen Elizabeth Hospital Birmingham)H-Index: 1
#2Charles Fong (Queen Elizabeth Hospital Birmingham)H-Index: 3
Last. Christopher M. Nutting (The Royal Marsden NHS Foundation Trust)H-Index: 73
view all 18 authors...
AIMS The De-ESCALaTE study showed an overall survival advantage for the administration of synchronous cisplatin chemotherapy with radiotherapy in low-risk oropharyngeal cancer when compared with synchronous cetuximab. During the trial, a radiotherapy quality assurance protocol amendment permitted centres to swap from the original radiotherapy contouring protocol (incorporating the whole oropharynx into the high-dose clinical target volume (CTV); anatomical protocol) to a protocol that incorporat...
#1Christopher M. Nutting (The Royal Marsden NHS Foundation Trust)H-Index: 73
#2Clare Griffin (ICR: Institute of Cancer Research)H-Index: 15
Last. Amen Sibtain (St Bartholomew's Hospital)H-Index: 2
view all 30 authors...
BACKGROUND Radical (chemo)radiotherapy offers potentially curative treatment for patients with locally advanced laryngeal or hypopharyngeal cancer. We aimed to show that dose-escalated intensity-modulated radiotherapy (DE-IMRT) improved locoregional control. METHODS We performed a phase III open-label randomised controlled trial in patients with laryngeal or hypopharyngeal cancer (AJCC III-IVa/b, TNM 7). Patients were randomised (1:1) to DE-IMRT or standard dose IMRT (ST-IMRT) using a minimisati...
#2Keith RooneyH-Index: 6
Last. S.A. BhideH-Index: 14
view all 14 authors...
BACKGROUND Previous studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, including those treated with immune checkpoint inhibitors (ICIs). We aimed to develop a model that predicts response and survival in patients with relapsed and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy. METHODS Analysis of 100...
#2Marcia S. Brose (UPenn: University of Pennsylvania)H-Index: 5
PURPOSE Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and an unmet need for effective treatment, especially for patients without BRAF mutations or NTRK or RET fusions. Lenvatinib is US Food and Drug Administration-approved for radioiodine-refractory differentiated thyroid cancer and has previously demonstrated activity in a small study of patients with ATC (n = 17). We aimed to further evaluate lenvatinib in ATC. METHODS This open-label, multicent...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.